05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of
cancer, oncology, tumors, solid and hematological tumors and
growths, hematological and hemolytic diseases and disorders,
including bone, joint, vertebral column, intestine, colon,
prostate, pancreatic, skin, lung, eye, breast, ovary,
cervix, stomach, bladder, kidney, head, brain, neck, and
blood diseases and disorders, including castration resistant
prostate cancer; pharmaceutical preparations for use in the
treatment of solid tumors and growths, hemolytic diseases
and disorders; pharmaceutical preparations for use in the
treatment of metastatic diseases; pharmaceutical
preparations for treating metabolic diseases and disorders;
pharmaceutical preparations for treating inflammatory and
autoimmune diseases and diseases; pharmaceutical
preparations for treating or preventing cardiovascular and
cerebrovascular diseases and disorders; pharmaceutical
preparations.
2.
BLINATUMOMAB WITH LOW-INTENSITY-CHEMOTHERAPY FOR USE IN TREATING ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of
cancer, oncology, tumors, solid and hematological tumors and
growths, hematological and hemolytic diseases and disorders,
including bone, joint, vertebral column, intestine, colon,
prostate, pancreatic, skin, lung, eye, breast, ovary,
cervix, stomach, bladder, kidney, head, brain, neck, and
blood diseases and disorders, including castration resistant
prostate cancer; pharmaceutical preparations for use in the
treatment of solid tumors and growths, hemolytic diseases
and disorders; pharmaceutical preparations for use in the
treatment of metastatic diseases; pharmaceutical
preparations for treating metabolic diseases and disorders;
pharmaceutical preparations for treating inflammatory and
autoimmune diseases and diseases; pharmaceutical
preparations for treating or preventing cardiovascular and
cerebrovascular diseases and disorders; pharmaceutical
preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of
cancer, oncology, tumors, solid and hematological tumors and
growths, hematological and hemolytic diseases and disorders,
including bone, joint, vertebral column, intestine, colon,
prostate, pancreatic, skin, lung, eye, breast, ovary,
cervix, stomach, bladder, kidney, head, brain, neck, and
blood diseases and disorders, including castration resistant
prostate cancer; pharmaceutical preparations for use in the
treatment of solid tumors and growths, hemolytic diseases
and disorders; pharmaceutical preparations for use in the
treatment of metastatic diseases; pharmaceutical
preparations for treating metabolic diseases and disorders;
pharmaceutical preparations for treating inflammatory and
autoimmune diseases and diseases; pharmaceutical
preparations for treating or preventing cardiovascular and
cerebrovascular diseases and disorders; pharmaceutical
preparations.
A system for measuring an air gap in a syringe having a plunger and containing a fluid of the present disclosure may include one or more processors configured to control a syringe imaging device to capture a first image of at least a portion of the syringe with the syringe imaging device oriented at a first rotational angle around a central syringe axis of the syringe with respect to a first central imaging axis of the syringe imaging device. The one or more processors may also be configured to control the syringe imaging device to capture a second image of at least a portion of the syringe with the syringe imaging device oriented at a second rotational angle around the central syringe axis with respect to a second central imaging axis. The one or more processors may be further configured to determine an air gap measurement between the plunger and fluid by analyzing at least the first image and the second image.
The disclosure relates to methods of improving sialic acid content of a therapeutic protein comprising expressing an α2,6-sialyltransferase-1 (ST6) or both ST6 and β1,4 galactosyltransferase 1 (B4GALT1) in a CHO cell; and culturing the cell in a medium comprising galactose and manganese.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The disclosure provides non-steady state continuous perfusion cell culture methods for protein production in bioreactors. Cells are cultured in non-steady state after entering production phase such that the viability declines over time. Production of protein products using these cell culture methods is increased.
The disclosure provides systems and methods for detecting and quantifying two or more different antigen-binding proteins in a sample. The systems involve donor beads, acceptor beads, and conjugate proteins, which may be incubated with the sample to quantify the antigen-binding proteins via a proximity-based homogenous assay.
This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed herein are compounds having activity as inhibitors of Werner Syndrome RecQ DNA helicase (WRN), pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to colorectal, endometrial, gastric and ovarian cancer. In particular, the disclosure provides compounds of Formula (A-I):
Disclosed herein are compounds having activity as inhibitors of Werner Syndrome RecQ DNA helicase (WRN), pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to colorectal, endometrial, gastric and ovarian cancer. In particular, the disclosure provides compounds of Formula (A-I):
Disclosed herein are compounds having activity as inhibitors of Werner Syndrome RecQ DNA helicase (WRN), pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to colorectal, endometrial, gastric and ovarian cancer. In particular, the disclosure provides compounds of Formula (A-I):
and pharmaceutically acceptable salts thereof, wherein the substituents are as described herein.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present disclosure relates to methods of characterizing low quantities of immunogen-binding protein, e.g., immunogen-binding antibodies obtained directly from supernatants of individually cultured B cells. These methods, which avoid hybridoma formation, involve providing a preparation of B cells that secrete immunogen-binding antibodies, and individually culturing the B cells under conditions suitable for the B cells to secrete the immunogen-binding antibodies into the culture supernatant. The culture supernatants containing the secreted antibodies are collected from the individually cultured B cells and subjected to one or more binding assays to characterize the immunogen-binding antibodies (e.g. as regards their binding affinity by exposing cell culture supernatants to increasing concentrations of immunogen) from the preparation of B cells.
The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the TTR gene. Methods of using such RNAi constructs to treat or prevent cardiac disease, such as transthyretin-associated cardiomyopathy (ATTR-CM), are also described.
Devices for storing a drug, placebo, and/or other substance(s) and related assemblies are disclosed. The device may include a container having a wall with an inner surface and an outer surface. The inner surface may at least partially define a reservoir for storing the drug, placebo, and/or other substance(s). The device may further include a film which is at least partially transparent. The film may include an adhesive layer configured to couple the film with the outer surface of the wall of the container. The film may further include a tinted layer configured to prevent or substantially inhibit a viewer from visually distinguishing whether at least one substance disposed in the reservoir corresponds to the drug or placebo. Additionally, the device may include a label coupled with the film and comprising readable information and/or instructions relating to the drug, placebo, and/or other substance(s).
Disclosed herein are compounds useful for the inhibition of IGF-1R. The compounds have a general Formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, an IGF-1R mediated disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
15.
Systems and Methods for Automated In-Line Plunger Depth Measurement
A system, comprising: one or more processors; and a memory storing executable instructions thereon that, when executed by the one or more processors, cause the one or more processors to: analyze a syringe scan of a syringe to determine (i) a first distance from a sensor to a first surface of the syringe and (ii) a second distance from the sensor to a second surface of the syringe, wherein the syringe scan is generated by the sensor scanning the syringe from a proximal end perspective, and the syringe scan is indicative of distance relative to the sensor; and calculate a distance between the first surface and the second surface based on the first distance and the second distance.
The present disclosure relates to an automated method for plating cells in a patch with different spot volumes in order to obtain at least one single, well spaced cell colony. There are multiple different spot volumes within each patch, and each spot is separated by a fixed distance. The disclosure further provides picking colonies by an automated method.
The disclosure provides methods for treating small cell lung cancer (SCLC) in a subject expressing human delta-like ligand 3 (DLL3) protein. The methods comprise administering to the subject an antigen-binding molecule comprising at least a first binding domain that binds to human DLL3, wherein at least 25% of the SCLC cells express DLL3, or wherein at least 25% of the SCLC cells express DLL3 at an intensity equal to or greater than 2+ as determined by an IHC assay.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention provides commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates thereof.
C07D 263/14 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
C07D 211/76 - Oxygen atoms attached in position 2 or 6
H04W 48/04 - Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction or speed
H04W 48/08 - Access restriction or access information delivery, e.g. discovery data delivery
H04W 76/38 - Connection release triggered by timers
19.
HETEROCYCLIC INHIBITORS OF IGF-1R AND USES THEREOF
Disclosed herein are compounds useful for the inhibition of insulin-like growth factor 1 receptor (IGF-1R). The compounds have a general Formula (I):
Disclosed herein are compounds useful for the inhibition of insulin-like growth factor 1 receptor (IGF-1R). The compounds have a general Formula (I):
Disclosed herein are compounds useful for the inhibition of insulin-like growth factor 1 receptor (IGF-1R). The compounds have a general Formula (I):
or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, thyroid-associated ophthalmopathy, Graves' opthalmopathy or Graves' orbitopathy. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Disclosed herein are pharmaceutical compositions (formulations) having reduced viscosity, using a low molecular weight polyvinylpyrrolidone (povidone) in the case of high therapeutic protein concentration (≥70 mg/ml) formulations. The addition of arginine, such as arginine monohydrochloride or N-acetyl arginine, can further reduce viscosity. Appropriate therapeutic proteins include antibodies, such as monoclonal antibodies, and derivatives, fragments, and analogues thereof.
Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).
Systems for inspecting one or more products on a production line and related methods are disclosed. The system (10) may include an optical scanner (22) and a frame (20). The optical scanner may be configured to scan at least one product of the product(s) (12a, 12b, 12c) on the production line (14) at a predetermined inspection location. The frame may be separate from the production line and configured to support the optical scanner adjacent to the at least one predetermined inspection. The frame may include a base (24) and vertical support (26) extending upwardly from the base. A top end of the vertical support may be configured to support the optical scanner adjacent to the predetermined inspection location. In some embodiments, the system may include a processing subsystem (32) configured to analyze output from the optical scanner to determine at least one characteristic of the at least one product on the production line, including, for example, the presence of label(s) (13a, 13b, 13c).
G01N 21/88 - Investigating the presence of flaws, defects or contamination
B65B 57/02 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of binding or wrapping material, containers, or packages
B65B 57/10 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of articles or materials to be packaged
G01N 21/90 - Investigating the presence of flaws, defects or contamination in a container or its contents
G01N 21/95 - Investigating the presence of flaws, defects or contamination characterised by the material or shape of the object to be examined
23.
HETEROCYCLIC INHIBITORS OF IGF-1R AND USES THEREOF
Disclosed herein are compounds useful for the inhibition of insulin-like growth factor 1 receptor (IGF-1R). The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, thyroid-associated ophthalmopathy, Graves' opthalmopathy or Graves' orbitopathy. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Convergent pathways for the preparation of a peptide by solid phase peptide synthesis or liquid phase peptide synthesis, as well as peptide fragments suitable for use in such pathways, are provided. The convergent pathways may be utilized for the synthesis of agonists of the glucagon-like peptide 1 receptor (GLP-1R) such as the peptide component of maridebart cafraglutide.
A method for facilitating selection of cell lines to advance to a next stage of cell line screening includes receiving first attribute values for the candidate cell lines measured using an opto-electronic cell line generation and analysis system, and acquiring second attribute values that include one or more attribute values measured at a cell pool screening stage of the candidate cell lines. The method also includes determining a ranking of the candidate cell lines according to a product quality attribute associated with hypothetical small-scale screening cultures. Determining the ranking includes predicting, for each of the candidate cell lines, a value of the product quality attribute by analyzing the first and second plurality of attribute values using a machine learning based regression estimator, and comparing the predicted values. The method also includes causing an indication of the ranking to be presented to a user via a user interface.
C12M 1/00 - Apparatus for enzymology or microbiology
C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Disclosed herein are various solid forms of Compound A, including crystalline and amorphous forms of Compound A free base, as well as salt forms, cocrystals, and solvates thereof. Also disclosed are methods of making the salt, cocrystal, and solvate forms, and methods of treating diseases and disorders with the salt, cocrystal, and solvate forms (Compound A).
C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
27.
COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as
or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Convergent pathways for the preparation of a peptide by solid phase peptide synthesis or liquid phase peptide synthesis, as well as peptide fragments suitable for use in such pathways, are provided. The convergent pathways may be utilized for the synthesis of agonists of the glucagon-like peptide 1 receptor (GLP-1R) such as the peptide component of maridebart cafraglutide.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
29.
TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic, and colorectal cancer. In particular, the disclosure provides compounds of Formula (II) and pharmaceutically acceptable salts thereof, wherein the substituents are as described.
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic, and colorectal cancer. In particular, the disclosure provides compounds of Formula (II) and pharmaceutically acceptable salts thereof, wherein the substituents are as described.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure provides techniques for accessing FADS1 activity in a patient. Also provided are techniques for determining the appropriateness of treatment of a patient with a FADS1 modulating (e.g., inhibiting) compound. This determination may be made by analyzing one or more biological indicators of FADS1-mediated disease or disorder in the subject. The one or more biological indicators may include one or more of a ratio of polyunsaturated fatty acids (“PUFAs”) in the subject, a relative abundance of one or more cell types, a relative abundance of one or more differentially expressed genes (“DEGs”) (or gene signatures, such as RNA, for such DEGs), and/or a relative abundance of one or more metabolites. Also disclosed are methods of using FADS1 inhibitors in methods of treating metabolic disorders and obesity.
Antigen binding molecules, chimeric receptors, and engineered immune cells to STEAP1 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the STEAP1 antigen binding molecules and engineered immune cells.
The disclosure provides solid forms of Compound A, as described herein. The disclosure also provides pharmaceutical compositions comprising the disclosed solid forms and methods of using the disclosed solid forms and pharmaceutical compositions (e.g., to treat cancer).
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.
The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
Biological detection systems and methods are disclosed for defining medically suitable target ranges of molecular attributes. A trial session dataset is received defining a set of subjects and biological experiment data of a test molecule provided to the set of subjects during a trial session. A principal component analysis (PCA) algorithm inputs such data and outputs principal component(s) defining a biological response to the test molecule and correlated with the test molecular attribute. A machine learning classifier inputs the principal component(s)and classifies a plurality of clusters based thereon. First and second positions of respective first and second clusters are selected to define control and sample datasets, respectively. A difference in direction and/or distance from an origin for the first and second positions is detected, and an effective target range is determined therefrom defining a range of attribute exposure values of the test molecule that has a medically suitable biological response correlated with the test molecular attribute.
G16C 20/70 - Machine learning, data mining or chemometrics
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
38.
T CELL ENGAGER MASKING MOLECULES WITH REDUCED ISOMERIZATION TENDENCIES
The present invention relates to T cell engager masking molecules, and methods related thereto, that contribute to reduce the severity of cytokine release syndrome, wherein said molecules comprise (i.) a binding peptide which is deprived of an isomerization site and which binds to a T-cell engaging paratope of a bispecific T cell engager molecule (TCE), (ii.) a linker, and (iii.) a half-life extending polymer.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Pharmaceutical compositions comprising anti-interleukin 12 (IL-12) interleukin 23 (IL-23) antibodies are described. The pharmaceutical compositions may comprise molecular attributes, such as oxidation of light chain W32, isoaspartic acid at heavy chain position D55; high molecular weight species such as dimers and/or oligomers, high mannose, sialylation, or acidic peak species. Method comprising administering the pharmaceutical compositions are described. Methods of manufacturing the pharmaceutical compositions are described.
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′ (I′) wherein the variables of Formula I′ are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′ (I′) wherein the variables of Formula I′ are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Systems and methods of performing line clearance and monitoring are disclosed herein. An example method includes receiving a first and second set of images of a manufacturing line during a run-time operation of the manufacturing line, the first set of images representing a first field of view (FOV) that is oriented to capture objects while falling from the manufacturing line, and the second set of images representing a second FOV that is different from the first FOV and oriented to capture objects positioned below the manufacturing line. The example method further includes analyzing the first set of images to identify a falling object; and analyzing the second set of images to identify a stationary object. The example method further includes, responsive to identifying the falling object or the stationary object, causing a display to present a notification that includes an image of the falling object or the stationary object.
Disclosed herein are compounds useful for the inhibition of STAT6. The compounds have a general Formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) and (II) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, diseases/disorders related to the activity of STAT6, such as an allergic disease or an inflammatory disease, including but not limited to atopic dermatitis or bronchial asthma. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I) and (II).
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 207/263 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
43.
DRUG DELIVERY DEVICES AND FLANGE EXTENSION MEMBERS
Drug delivery devices and flange extension members for syringes are disclosed. A drug delivery device may include a syringe and a flange extension member. The syringe may include a barrel having a proximal end, a distal end, and a longitudinal axis. The syringe may additionally include a flange disposed at the proximal end of the barrel and extending radially outwardly or substantially radially outwardly with respect to the longitudinal axis. The flange extension member may be coupled with at least the flange of the syringe. The flange extension member may comprise at least one anti-rotation member engaging at least one of the barrel of the syringe and the flange of the syringe to inhibit or prevent the flange extension member from rotating with respect to the longitudinal axis.
Provided herein are methods of determining the concentration of diethylenetriamene pentaacetate (DTPA) in a pharmaceutical formulation. In exemplary embodiments, the method comprises providing (i) a reference standard comprising, citrate and a known concentration of DTPA and (ii) a sample of a pharmaceutical formulation comprising DTPA, citrate and a protein; wherein the citrate concentration of the reference standard is the same as the citrate concentration of the sample of the pharmaceutical formulation; wherein each of the reference standard and the sample of the pharmaceutical formulation further comprise iron and the iron concentration of the reference standard is the same as the iron concentration of the sample of the pharmaceutical formulation and the iron present in each of the reference standard and sample is in excess of the citrate present in each of the reference standard and sample, and applying each of the reference standard and sample to an RPLC column.
Systems and methods that facilitate the automatic (or substantially automatic) preparation of a sample of a product containing molecules for analysis and automatic (or substantially automatic) performance of an assay of that sample. Thus, the preparation and analysis can be performed substantially in-real time, or, in other words, much more quickly than presently allowed by conventional systems and methods.
Disclosed herein are compounds useful for the inhibition of STAT6. The compounds have a general Formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) and (II) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, diseases/disorders related to the activity of STAT6, such as an allergic disease or an inflammatory disease, including but not limited to atopic dermatitis or bronchial asthma. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I) and (II).
Disclosed herein are compounds useful for the inhibition of STAT6. The compounds have a general Formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) and (II) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, diseases/disorders related to the activity of STAT6, such as an allergic disease or an inflammatory disease, including but not limited to atopic dermatitis or bronchial asthma. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I) and (II).
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 207/27 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present application relates, in general, to compositions comprising anti-TSLP antibody, such as tezepelumab, and derivatives thereof having antibody quality attributes.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
The present invention relates to methods of treating obesity or type II diabetes using an antagonistic anti-GIPR antibody conjugated to a GLP-1R agonist. In particular, methods for treating obesity or type II diabetes in a patient in need thereof comprising administering to the patient an antagonistic anti-GIPR antibody conjugated to a GLP-1R agonist according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising an antagonistic anti-GIPR antibody conjugated to a GLP-1R agonist for use in the methods are also described.
The present disclosure provides method of administering sotorasib to a patient, e.g., a patient with a cancer comprising a KRAS G12C mutation, wherein the patient is further in need of treatment with a breast cancer resistance protein (BCRP), e.g., rosuvastatin.
The present invention provides multichain multitargeting bispecific antigen-binding molecules characterized by comprising a first and a second bispecific entity each comprising a domain binding to a target, a second domain binding to an extracellular epitope of the human and the Macaca CD3ε chain, wherein both bispecific entities are linked to each other by a spacer which spaces apart the first and the second bispecific entity. Moreover, the invention provides a polynucleotide, encoding the multitargeting bispecific antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A load vessel draining system for use with a drug purification system. The system includes a load vessel, a liquid handling module coupled to the load vessel and configured to draw fluid from the load vessel, and a chase solution vessel coupled to the load vessel. A backflow mechanism is coupled to each of the chase solution vessel and the load vessel, and the backflow mechanism is configured to at least selectively prevent fluid from the load vessel from prematurely backflowing into the chase solution vessel. So configured, the chase solution from the chase solution vessel is added to the load vessel upon one or more of: (1) the load vessel reaching an empty state; or (2) pressure within the load vessel exceeding a predetermined threshold.
This disclosure relates to methods of treating KRAS G12C mutant non-small cell lung cancer (NSCLC) by administering a triple combination therapy including defactinib, avutometinib, and sotorasib in a subject such as humans.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medicaments, namely, polypeptides, for use in the treatment of tumorous diseases, cancer, allergies, autoimmunity, inflammation, osteoporosis, graft versus host diseases, transplant rejection, cardiovascular diseases, metabolic diseases, neurological diseases, and minimal residual diseases Downloadable educational materials, namely, video recordings, books, and printable booklets on therapeutic polypeptides and use thereof Providing medical and scientific research information regarding therapeutic polypeptides and use thereof; providing a website featuring medical and scientific research information regarding antibody derivatives and use thereof; providing scientific information regarding antibody derivatives and use thereof
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of osteoporosis, management of osteoporosis and fracture risk reduction Providing medical information; Providing health information; Providing health information in the field of osteoporosis and fracture risk reduction, and management of osteoporosis care
64.
BISPECIFIC LYMPHOTOXIN B RECEPTOR BINDING PROTEINS
The present disclosure is directed to bispecific binding proteins and their utility for treating cancer. The disclosed bispecific binding proteins comprises a LTβR binding domain that binds to one or more amino acid residues of human LTβR cysteine-rich domain 4 (CRD4), where the human LTβR CRD4 comprises amino acid residues 169-211 of human LTβR (SEQ ID NO: 1). The disclosed bispecific binding proteins further comprises a fibroblast activation protein alpha (FAP) binding domain. The bispecific binding proteins (i) agonize LTβR, (i) do not inhibit LIGHT binding to LTβR, and (ii) do not inhibit LT1α2β binding to LTβR.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A method for monitoring and/or controlling a pharmaceutical process includes obtaining one-dimensional spectral data generated by a spectroscopy system (e.g., a Raman spectroscopy system), converting the one-dimensional spectral data to a two-dimensional spectral data matrix, and applying the two-dimensional spectral data matrix to an input layer of a deep learning model (e.g., a convolutional neural network). The deep learning model predicts a parameter (e.g., metabolite level) based on the two-dimensional spectral data matrix, e.g., in order to monitor and/or control a pharmaceutical process.
A method of controlling a cell culture process uses hybrid predictive modeling in a model predictive controller. The method CCPC application includes, for multiple time intervals, obtaining current values of cell culture attributes associated, and generating a control value for a physical input to the cell culture process. Generating the control value includes predicting future values of the cell culture attributes based on the current values, by using one or more data-driven models to predict future values of a first one or more attributes of the cell culture attributes, and using one or more first principle models to predict future values of a second one or more attributes of the cell culture attributes. Generating the control value also includes determining the control value by optimizing an objective function subject to the predicted future values. The method also includes using the control value to control the physical input to the cell culture process.
Methods for monitoring cell aging of manufacturing cell lines based on next generation sequencing (NGS) are provided. The methods can predict stability risks in a biologic-producing cell line.
The present invention relates to methods of treating obesity and obesity-related conditions. The claimed methods can be used to reduce gastrointestinal side-effects associated with administration of GLP-1R agonists. Included also are titrations of maridebart cafraglutide doses.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of diabetes,
endocrine diseases and disorders, metabolic diseases and
disorders, and obesity; pharmaceutical preparations for
weight reduction and long-term weight loss maintenance.
70.
DRIVE ASSEMBLY FOR A DRUG DELIVERY DEVICE AND RELATED METHODS
Drive assemblies for a drug delivery device and related methods are disclosed. A drive assembly comprises a casing having a proximal end, a distal end, and a longitudinal axis extending between the proximal end and the distal end, a plunger rod guide operably coupled to the casing, a spring at least partially disposed within the casing and wound around at least a portion of the plunger rod guide, and a lock component selectively coupled with the casing and configured to receive at least a portion of the plunger rod guide therein. The spring is configured to exert a force on the plunger rod guide that causes the plunger rod guide to rotate. The lock component is configured to prevent rotational movement of the plunger rod guide relative to the casing when the lock component is coupled with the casing.
Drive assemblies for a drug delivery device and related methods are disclosed. A drive assembly comprises a casing having a proximal end, a distal end, and a longitudinal axis extending between the proximal end and the distal end, a plunger rod guide operably coupled to the casing, a spring at least partially disposed within the casing and wound around at least a portion of the plunger rod guide, and a lock component selectively coupled with the casing and configured to receive at least a portion of the plunger rod guide therein. The spring is configured to exert a force on the plunger rod guide that causes the plunger rod guide to rotate. The lock component is configured to prevent rotational movement of the plunger rod guide relative to the casing when the lock component is coupled with the casing.
Provided herein are methods of treating a cancer in a patient wherein the patient has a KRAS G12C mutation, comprising administering to the patient a therapeutically effective combination of sotorasib and RMC-4630.
The present invention relates to methods of reducing weight, HbA1c levels, high-sensitivity C-reactive protein, and systolic blood pressure in human patients comprising administering to the patient maridebart cafraglutide with the result being treatment of obesity, type II diabetes, and other obesity related conditions such as atherosclerotic cardiovascular disease and heart failure.
Provided herein are methods of treating, inhibiting, reducing, or ameliorating cardiovascular adverse events in a patient caused by administration of carfilzomib by administering to the patient at least one of a soluble guanylyl cyclase (sGC) activator, a PDE5 inhibitor, p38 inhibitor, and/or MAPKAPK-2 inhibitor.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Systems and methods for inspecting one or more drug containers (10) disposed in a processing tray (11) are disclosed. A system (100) includes an imaging system (112) and a processing system (114). The imaging system (112) can include an image sensor (140) and a telecentric lens (146) and be configured to generate one or more images of the one or more drug containers (10) disposed in the processing tray (11). The processing system (114) can be configured to analyze the one or more images to determine a count of the one or more drug containers (10) disposed in the processing tray (11). A method includes generating (1103), by an imaging system (112) comprising an image sensor (140) and a telecentric lens (146), one or more images of one or more drug containers (10) disposed in a processing tray (11); and analyzing (1104), by one or more processors (114), the one or more images to determine a count (1006, 1105) of the one or more drug containers (10) disposed in the processing tray (11).
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
77.
CANCER TREATMENTS USING MTA-COOPERATIVE PRMT5 INHIBITORS AND MAT2A INHIBITORS
Described herein are methods of treating cancer in a patient comprising administering a combination therapy of a therapeutically effective amount of a PRMT5 inhibitor (Compound A) and a therapeutically effective amount of a MAT2A inhibitor (Compound B) to the patient.
Provided herein is a therapy of Compound G, or pharmaceutically acceptable salt thereof, and Compound A, or pharmaceutically acceptable salt thereof, for treating an MTAP-null cancer in a subject in need of treatment.
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to a polypeptide or a polypeptide construct comprising a domain which binds to Claudin 6 (CLDN6) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the construct of the invention, a medical use of said construct and a kit comprising said construct.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic, and colorectal cancer. In particular, the disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the substituents arm as described.
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic, and colorectal cancer. In particular, the disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the substituents arm as described.
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof
C07D 451/14 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantaneCyclic acetals thereof
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
An apparatus is for nondestructive detection of one or more transparent or reflective objects in a vessel that is at least partially filled with a fluid. The apparatus comprises an imager, a memory and a processor. The imager is configured to acquire data that represent light reflected from a plurality of spatial locations in the vessel as a function of time. The memory is operably coupled to the imager and configured to store the data. The processor is operably coupled to the memory and configured to detect the objects based on the data by: (i) identifying a respective maximum amount of reflected light for each location in the plurality of locations, and (ii) determining a presence or absence of the objects in the vessel based on the number of spatial locations whose respective maximum amount of reflected light exceeds a predetermined value.
An apparatus for injection of a therapeutic product, the apparatus comprising: an autoinjector; and a single-use cassette for use with the injector, the cassette comprising: a housing; a sleeve disposed in the housing and movable between first and second positions; a syringe disposed in the sleeve; and a shield remover extending through an opening in a proximal end of the housing for removing a needle shield from the syringe.
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 51/15 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
C07C 51/60 - Preparation of carboxylic acid halides by conversion of carboxylic acids or their anhydrides into halides with the same carboxylic acid part
A drug delivery device (10, 100, 200) which includes a housing (12, 112, 212) having a distal end, a proximal end, and an opening adjacent to the distal end, a drug storage container (20) including a delivery member (16) having an insertion end configured to extend at least partially through the opening, a plunger moveable (26) in a distal direction to expel a drug from the drug storage container through the delivery member, a guard member (32, 132, 232) moveable relative to the housing, and a guard extension (37, 137, 237) positioned proximal to the guard member and operably coupled to the guard member. The guard extension may have a first engagement component on an inner surface thereof, and the guard member may have a second engagement component. The first and second engagement components are configured to limit axial movement of the guard extension in a proximal direction when the guard member is in the extended position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
87.
5,6-FUSED BICYCLIC ALCOHOL COMPOUNDS AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS
Disclosed herein are compounds useful for the inhibition of 15-PGDH. The compounds have a general Formula (I): (I) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a 15-PGDH-mediated disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
88.
DRUG DELIVERY DEVICES, COMPONENTS FOR USE WITHIN DRUG DELIVERY DEVICES, AND METHODS OF OPERATING DRUG DELIVERY DEVICES
Drug delivery devices, components for use within drug delivery devices, and methods of operating drug delivery devices are provided. A drug delivery device may include using a real-time clock of a wireless communication module to communicate data with a remote device when a main microcontroller is in a sleep mode. A drug delivery device may include disabling communication between a main microcontroller and a wireless communication module when the main microcontroller during an injection process. A drug delivery device may include determining an end of an injection process based on data from an insertion drive and an extrusion drive. A drug delivery device may include dual proximity sensors with unique thresholds. A drug delivery device may include electrostatic discharge protection and recovery.
Disclosed herein are compounds useful for the inhibition of 15-PGDH. The compounds have a general Formula (I):
Disclosed herein are compounds useful for the inhibition of 15-PGDH. The compounds have a general Formula (I):
Disclosed herein are compounds useful for the inhibition of 15-PGDH. The compounds have a general Formula (I):
or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a 15-PGDH-mediated disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
Methods of determining glycan pairing content of a protein composition are provided. In exemplary embodiments, the method comprises (a) treating a sample of the protein composition with (i) a mannosidase and (ii) a β1-4 endoglycosidase, to produce a mixture of components of the protein, wherein at least some of the components comprises one or more digested glycan structures; and (b) separating the components of the mixture based on molecular weight; and (c) quantifying the abundance of glycan pairs, optionally, quantifying (i) paired afucosylated glycans, (ii) unpaired afucosylated glycans, (iii) paired high mannose glycans, and/or (iv) unpaired high mannose glycans, of the mixture. In exemplary aspects, the method comprises quantifying the relative unpaired afucosylated (AF) glycan content and/or relative unpaired high mannose (HM) glycan content of the mixture.
A drug delivery device may include a housing having a distal end, a proximal end, and an opening adjacent to the distal end, a flange protruding radially inward from an inner surface of the housing, a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening, a plunger moveable in a distal direction to expel a drug from the drug storage container through the delivery member, a guard moveably positioned adjacent to the opening, a guard extension positioned proximal to the guard and operably coupled to the guard, a releaser member operably coupled to the guard extension, the releaser member having a distally facing contact surface, and a first biasing member disposed between the flange of the housing and the distally facing contact surface of the releaser member. The first biasing member may be configured to bias the releaser member in a proximal direction in at least a pre-delivery state.
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing online non-downloadable informational content in the field of musculoskeletal health and fracture risk reduction; Providing a website featuring non-downloadable informational content relating to musculoskeletal wellness and fracture awareness; Providing online non-downloadable digital content to promote public awareness of musculoskeletal health and fracture risk reduction
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing online non-downloadable informational content in the field of musculoskeletal health and fracture risk reduction; Providing a website featuring non-downloadable informational content relating to musculoskeletal wellness and fracture awareness; Providing online non-downloadable digital content to promote public awareness of musculoskeletal health and fracture risk reduction
